(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.73%) $83.24
(-1.16%) $1.619
(-0.09%) $2 345.00
(-0.16%) $27.49
(0.38%) $925.60
(-0.10%) $0.934
(-0.08%) $11.02
(-0.16%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases...
Stats | |
---|---|
今日成交量 | 204 800 |
平均成交量 | 201 179 |
市值 | 5.57B |
EPS | SEK0 ( 2024-02-20 ) |
下一个收益日期 | ( SEK-1.240 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -11.93 |
ATR14 | SEK0.251 (0.24%) |
音量 相关性
Calliditas Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Calliditas Therapeutics 相关性 - 货币/商品
Calliditas Therapeutics 财务报表
Annual | 2023 |
营收: | SEK1.21B |
毛利润: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
营收: | SEK1.21B |
毛利润: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
营收: | SEK0 |
毛利润: | SEK0 (0.00 %) |
EPS: | SEK0 |
FY | 2022 |
营收: | SEK802.88M |
毛利润: | SEK787.68M (98.11 %) |
EPS: | SEK-7.78 |
Financial Reports:
No articles found.
Calliditas Therapeutics
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。